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OBJECTIVES We sought to determine the effect of angiotensin receptor blockers (ARBs) on mortality and
hospitalization in patients with heart failure (HF).
BACKGROUND There is uncertainty regarding the efficacy of ARBs as substitute or adjunctive therapy to
angiotensin-converting enzyme inhibitors (ACEIs) in the treatment of HF.
METHODS We conducted a meta-analysis of all randomized controlled trials that compared ARBs with
either placebo or ACEIs in patients with symptomatic HF. The pooled outcomes were
all-cause mortality and hospitalization for HF.
RESULTS Seventeen trials involving 12,469 patients were included. Overall, ARBs were not superior to
controls in the pooled rates of death (odds ratio: 0.96; 95% confidence interval: 0.75 to 1.23)
or hospitalization (0.86; 0.69 to 1.06). Stratified analysis, however, showed a non-significant
trend in benefit of ARBs over placebo in reducing mortality (0.68; 0.38 to 1.22) and
hospitalization (0.67; 0.29 to 1.51) when given in the absence of background ACEI therapy.
When compared directly with ACEIs, ARBs were not superior in reducing either mortality
(1.09; 0.92 to 1.29) or hospitalization (0.95; 0.80 to 1.13). In contrast, the combination
therapy of ARBs and ACEIs was superior to ACEIs alone in reducing hospitalization (0.74;
0.64 to 0.86) but not mortality (1.04; 0.91 to 1.20).
CONCLUSIONS This meta-analysis cannot confirm that ARBs are superior in reducing all-cause mortality or
HF hospitalization in patients with symptomatic HF, particularly when compared with
ACEIs. However, the use of ARBs as monotherapy in the absence of ACEIs or as
combination therapy with ACEIs appears promising. (J Am Coll Cardiol 2002;39:463–70)
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The use of angiotensin receptor blockers (ARBs) as substi-
tute or adjunctive therapy to angiotensin-converting enzyme
inhibitors (ACEIs) in the treatment of heart failure (HF)
remains controversial. Although randomized controlled
trials have shown conclusively that ACEIs reduce mortality
and hospitalization in patients with HF (1), trials with
ARBs in similar HF populations have qualitatively reached
mixed conclusions. This is despite the theoretical superiority
of ARBs over ACEIs in improving blockade of the renin-
angiotensin-aldosterone system (2,3). A recent meta-
analysis using data from six small studies has suggested a
survival benefit with losartan when compared with either
placebo or ACEIs in patients with HF (4). That meta-
analysis, however, did not include data from the large
Evaluation of Losartan in the Elderly II trial (5). This latter
study, published subsequent to the meta-analysis, did not
demonstrate a mortality benefit with losartan when com-
pared with captopril in patients with HF. Furthermore, the
meta-analysis did not include randomized trials that com-
pared other ARBs with standard care. Given the limitations
of existing data and their potential impact on the prescribing
practices of these two drug classes in the HF population, we
undertook a quantitative meta-analysis of all relevant ran-
domized controlled trials to determine the effect of ARBs
on the survival and hospitalization rates in patients with
HF.
METHODS
Search strategy. The protocol of this study has been
published elsewhere under the aegis of Cochrane Collabo-
ration (6). In brief, we performed a systematic search (7,8)
for randomized controlled trials published between 1966
and May 2001 from the following databases: MEDLINE,
EMBASE, Biological Abstracts, International Pharmaceu-
tical Abstracts, Cochrane Controlled Trials Database, Mc-
Master Cardiovascular Randomized Clinical Trial Registry
and Science Citation Index. We used the keywords of heart
or cardiac failure, cardiac insufficiency, cardiomyopathy, angio-
tensin receptor blockers, antagonists or inhibitors, along with
individual drug names and their registry numbers.
Selection criteria. We included only studies that met the
following criteria: enrolment of patients with New York
Heart Association (NYHA) functional class II to IV HF,
comparison of ARBs with placebo or ACEIs, randomized
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allocation, parallel-group design, blinded studies and treat-
ment duration of at least four weeks. Included studies must
report death or hospitalization as clinical efficacy or safety
end points. Studies that required the co-administration of
non-randomized investigational agents were excluded. We
excluded studies that were published in non-peer reviewed
journals or only as abstracts.
Study outcomes. Relevant trials were identified by consen-
sus. Outcome data were independently extracted by two
reviewers, and disagreements were resolved by consensus or
a third reviewer. Adequacies of random allocation, blinding
and descriptions of withdrawals and dropouts were individ-
ually judged for each trial. Study authors and pharmaceuti-
cal companies were contacted to clarify insufficiencies of the
published data.
Our primary outcome was all-cause mortality. Our sec-
ondary outcome was hospitalization for HF. We defined
hospitalization for HF as a hospital admission for worsening
signs or symptoms of HF or for complications relating to
the treatment of HF or for syncope or arrhythmias related to
acute exacerbations of HF.
Statistical analysis. All analyses were based on the
intention-to-treat principle. Crude treatment effects for
each study were reported as standard odds ratios (ORs).
Pooled ORs and the 95% confidence intervals (CIs) were
calculated based on the Mantel-Haenszel method (9) for
fixed effects models and the methods of DerSimonian and
Laird (10) for random effects models. A continuity correc-
tion factor (11) was added in order to avoid division by zero.
The chi-square test for heterogeneity was used to test for the
assumption of a fixed effects model (p  0.10).
In our primary analysis, all ARBs were combined regard-
less of dosages, assuming a class effect and analyzed regard-
less of the types of controls (placebo or ACEI). Combina-
tion therapy with ARBs and ACEIs were analyzed as the
ARB arm and compared with controls. For studies with
more than one control arm (such as both placebo and
ACEI), all controls were combined to form one “mixed”
control arm and compared with the ARB arm. Random
effects models were used to report the primary analysis.
Secondary stratified analyses were conducted to refine the
types of treatment comparison. Three treatment compari-
sons were made: 1) ARBs versus placebo, without back-
ground ACEI therapy; 2) ARBs versus ACEIs; and 3)
combination therapy of ARBs and ACEIs versus ACEIs
alone. The latter comparison included trials that compared
ARBs with placebo where background open-label ACEI
therapy was given. Fixed effects models were used to report
all stratified analyses.
To determine the robustness of our pooled effects, we
compared our primary analysis with fixed effects and ran-
dom effects models. We also compared our stratified anal-
yses with our primary analysis to determine whether any
observed heterogeneity in the treatment effects of ARBs was
partly due to differences in the types of controls with which
ARBs were compared. We recalculated the pooled effect
estimates using Peto OR (12) and then compared them with
those calculated using the methods of DerSimonian and
Laird (10). Pooled estimates were also recalculated after
excluding either: 1) studies that included only ACEI-
intolerant patients; or 2) studies that lasted less than six
months. We defined a pooled treatment effect to be quali-
tatively robust if the upper and lower confidence bounds for
the pooled effect would remain unchanged in direction with
respect to unity. A funnel plot (13) of all included trials was
used to check for the presence of publication bias. Power
calculations (14) were used to determine the minimal effect
sizes detectable by our analysis. All analyses were conducted
using the RevMan 4.1 (7) and SAS 8.0 (Cary, North
Carolina) statistical packages.
RESULTS
Literature search. Our search identified 17 relevant trials
(Table 1). Twenty-six studies were excluded for the follow-
ing reasons: data published as abstracts only (n  6);
crossover trials (n  4), singe-dose study (n  5); inappro-
priate study population (n  3), lack of appropriate controls
(n  2); non-randomized study (n  2); failure to report
clinical events (n  2); and duplicated study (n  2). Three
trials (Candesartan in Heart Failure—Assessment of Re-
duction in Mortality and Morbidity trial [CHARM] [15],
Optimal Therapy in Myocardial Infarction with the Angio-
tensin II Antagonist Losartan trial [OPTIMAAL] [16] and
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ADEPT  Addition of the AT1 Receptor
Antagonist Eprosartan to ACE
Inhibitor Therapy in Chronic Heart
Failure trial
ARB  angiotensin receptor blocker
CHARM  Candesartan in Heart
Failure—Assessment of Reduction in
Mortality and Morbidity trial
CI  confidence interval
ELITE  Evaluation of Losartan In The Elderly
study
HF  heart failure
NYHA  New York Heart Association
OPTIMAAL  Optimal Therapy in Myocardial
Infarction with the Angiotensin II
Antagonist Losartan trial
OR  odds ratio
RESOLVD  Randomized Evaluation of Strategies for
Left Ventricular Dysfunction pilot study
SPICE  Study of Patients Intolerant of
Converting Enzyme inhibitors
STRETCH  Symptom, Tolerability, Response to
Exercise Trial of Candesartan cilexetil in
Heart failure
V-HeFT  Vasodilator Heart Failure Trial
Val-HeFT  Valsartan Heart Failure Trial
VALIANT  Valsartan in Acute Myocardial
Infarction
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Table 1. Characteristics of Randomized Trials on ARBs in HF That Were Included in the Meta-analysis
Trials Participants n Drugs Controls
Mean
Follow-up
Background
ACEI Outcomes
ADEPT 2001 (20) NYHA II–IV, LV EF 35% 36 Eprosartan 400 mg BID Placebo 8 weeks Yes Primary: EF; secondary; hemodynamics,
neurohormones
Crozier 1995 (19) NYHA II–IV, LV EF 40%,
PCWP 13 mm Hg
134 1) Losartan 2.5 mg OD;
2) losartan 10 mg OD;
3) losartan 25 mg OD;
4) losartan 50 mg OD
Placebo 12 weeks No Primary: PCWP; secondary; clinical status,
tolerability
Dickstein 1995 (27) NYHA III–IV, LV EF 35% 166 1) Losartan 25 mg OD,
2) losartan 50 mg OD
Enalapril 10 mg BID 8 weeks No Primary: exercise capacity, clinical status,
neurohumoral activation
ELITE 1997 (28) NYHA II–IV, LV EF 40%,
no prior ACEI, age 65
722 Losartan 50 mg OD Captopril 50 mg TID 48 weeks No Primary: renal dysfunction; secondary:
all-cause mortality, HF hospitalization
ELITE II 2000 (5) NYHA II–IV, LV EF 40% 3,152 Losartan 50 mg OD Captopril 50 mg TID 1.5 years No Primary: all-cause mortality; secondary:
composite of sudden cardiac death or
resuscitated cardiac arrest
Hamroff 1999 (21) NYHA III–IV 33 Losartan 50 mg OD Placebo 6 months Yes Primary: peak aerobic capacity, NYHA functional
class; secondary: laboratory safety parameters,
doses of concomitant background medications
Lang 1997 (29) NYHA II–IV, LV EF 45% 116 1) Losartan 25 mg OD;
2) losartan 50 mg OD
Enalapril 10 mg BID 12 weeks No Primary: exercise tolerance, clinical status;
secondary: EF
Mazayev 1998 (30) NYHA II–IV, PCWP 15
mm Hg
116 1) Valsartan 40 mg BID;
2) valsartan 80 mg BID;
3) valsartan 160 mg BID
1) Placebo;
2) Iisinopril 10 mg
OD
4 weeks No Primary: PCWP, adverse events; secondary:
CO, SVR
Phase III Int’l 1996 (4) NYHA II–IV, EF 40% 385 Losartan 50 mg OD Placebo 12 weeks No Primary: exercise capacity
Phase III US 1995 (4) NYHA II–IV, EF 40% 351 Losartan 50 mg OD Placebo 12 weeks No Primary: exercise capacity
RESOLVD 1999 (31) NYHA II–IV, LV EF 40%,
6-min walk distance
500 m
768 1) Candesartan 4 mg OD;
2) candesartan 8 mg OD;
3) candesartan 16 mg OD
1) Enalapril 10 mg
BID; 2) placebo
43 weeks No Primary: 6-min walk distance, EF, ventricular
volume, neurohormone level, QOL, NYHA
SPICE 2000 (22) NYHA II–IV, LV EF 35% 270 Candesartan 16 mg OD Placebo 12 weeks No Primary: tolerability; secondary: adverse events,
clinical events, QOL, functional status
STRETCH 1999 (23) NYHA II–III,
LV EF 30%–45%
844 1) Candesartan 4 mg OD;
2) candesartan 8 mg OD;
3) candesartan 16 mg OD
Placebo 12 weeks No Primary: exercise time; secondary: clinical status,
cardiothoracic ratio, neuroendocrine parameters
Tonkon 2000 (24) NYHA II–III, LV EF 40% 109 Irbesartan 150 mg OD Placebo 12 weeks Yes Primary: ETT; secondary: LV EF, clinical status,
safety
V-HeFT 1999 (25) NYHA II–IV,
PCWP 15 mm Hg
83 1) Valsartan 80 mg BID;
2) valsartan 160 mg BID
Placebo 4 weeks Yes Primary: PCWP; secondary: hemodynamics,
neurohormones
Val-HeFT 2001 (18) NYHA II–IV, LV EF 40% 5,010 Valsartan 160 mg BID Placebo 23 months Yes Primary: all-cause mortality, combined all-cause
mortality and morbidity (hospitalization,
resuscitated sudden death, IV inotropic or
vasodilator support)
Weber 1997 (26) NYHA II–IV 154 Losartan 2.5–50 mg OD Placebo 12 weeks No Primary: safety
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BID  twice a day; CO  cardiac output; EF  ejection fraction; ETT  exercise tolerance time; HF  heart failure; IV  intravenous; LV 
left ventricle; NYHA  New York Heart Association; OD  once daily; PCWP  pulmonary capillary wedge pressure; QOL  quality of life; SVR  systemic vascular resistance; TID  three times a day. 465
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Valsartan in Acute Myocardial Infarction [VALIANT]
[17]) are ongoing.
Study characteristics. All were randomized, double-blind,
controlled trials. A total of 12,469 patients were random-
ized: 7,060 to ARBs and 5,409 to controls (placebo or
ACEIs). Eleven trials (4,18–26) used placebo as controls.
Four trials (5,27–29) used ACEIs as controls. Two trials
(30,31) included both a placebo and an ACEI arm as
controls. Background open-label ACEI therapy was man-
datory or recommended in five of the 11 placebo-controlled
trials (18,20,21,24,25). This was in contrast to one trial (22)
that enrolled only ACEI-intolerant patients. Ten trials
(5,18,20,22–25,27–30) employed a placebo or drug-free
run-in period, whereas two trials (21,31) employed an active
therapy run-in period. All but two trials (21,26) required
objective documentation of left ventricular systolic dysfunc-
tion. The proportions of NYHA IV HF subjects across the
studies were small (2% to 15%). The mean age of partici-
pants ranged between 56 and 73 years. Male subjects
comprised 48% to 100% of the enrollees. The studies were
dominated by whites (59% to 100%).
Five ARBs were tested in this meta-analysis: losartan (in
nine trials), candesartan (in three trials), valsartan (in three
trials), irbesartan (in one trial) and eprosartan (in one trial).
Mean duration of treatment varied from four weeks to 1.5
years.
Methodological quality. Only one trial (23) gave explicit
description of the randomization method. Given, however,
all but two trials (20,21) were multicenter in design, it
would be unlikely that the allocation method was flawed to
such an extent as to influence the outcome of our analysis.
Five trials (19,21,25,26,29) did not disclose methods of
double blinding to judge their adequacies. Two trials (4) did
not disclose any information on withdrawals or dropouts.
Mortality. All-cause mortality was reported in all trials. A
total of 1,674 deaths were recorded. Overall, there was no
statistical difference in the pooled mortality rate between the
ARB and control group (OR: 0.96; 95% CI: 0.75 to 1.23;
n  7,060 vs. n  5,409; Fig. 1). Heterogeneity of
borderline significance was observed in the pooled estimate
across the trials (p  0.10). This heterogeneity was reduced
when the analysis was stratified into one of the three
ARB-ACEI-placebo treatment comparisons (Fig. 2).
Among trials where background ACEIs were not given, the
pooled estimate favored ARBs over placebo in improving
survival (OR: 0.68; n  1,628 vs. n  631), albeit limited
sample size prevented it from attaining statistical signifi-
cance (95% CI: 0.38 to 1.22). In contrast, among trials that
directly compared ARBs with ACEIs, ARBs were not
superior in improving survival (1.09; 0.92 to 1.29; n 2,518
vs. n  2,164). When the combination therapy of ARBs
and ACEIs was compared with ACEIs alone, the risks of
death were virtually identical (1.04; 0.91 to 1.20; n  2,989
vs. n  2,723).
Hospitalization. Hospitalization for HF was reported in
only six trials. A total of 1,515 hospitalizations (first event)
were recorded. Overall, there was no statistical difference in
the pooled rate of hospitalization between the ARB and
control groups (0.86; 0.69 to 1.06; n 5,336 vs. n 4,695;
Fig. 3). Once again, heterogeneity of borderline significance
was observed in the pooled estimate across the trials (p 
0.11). This heterogeneity was reduced when the analysis
was stratified by specific treatment comparisons (Fig. 4).
Only one trial that compared ARBs with placebo without
background ACEI therapy reported on hospitalization; it
Figure 1. Comparison of angiotensin receptor blockers versus controls on all-cause mortality. Controls were either placebo or angiotensin-converting
enzyme inhibitor (ACEI). Odds ratios (OR) and the 95% confidence intervals (CI) are shown on a logarithmic scale, with box size proportional to the
sample size. The diamond represents the pooled effect. Acronyms as in Abbreviations and Acronyms box.
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showed a non-significant trend in benefit favoring the ARB
group (0.67; 0.29 to 1.51; n  179 vs. n  91). In the
stratified comparison of ARBs with ACEIs, no difference in
the rate of hospitalization was seen (0.95; 0.80 to 1.13; n 
2,257 vs. n  2,053). In contrast, the combination therapy
of ARBs and ACEIs showed a statistically significant
benefit in reducing hospitalization over ACEIs alone (0.74;
0.64 to 0.86; n  2,900 vs. n  2,660).
Sensitivity analyses. Our analyses were largely robust, with
a few exceptions, in both the choices of models and the
statistical methods. The substitution of a fixed model for a
random effects model did not change our initial qualitative
interpretation of the pooled treatment effect on mortality,
but it resulted in a statistically significant benefit of reduced
hospitalization in favor of ARBs. Likewise, using pooled
ORs obtained by the Peto method instead of the methods
of DerSimonian and Laird (10) did not change our initial
qualitative interpretation in the pooled treatment effect on
mortality but resulted in a statistically significant benefit in
reducing hospitalization now seen in favor of ARBs. Nei-
ther the exclusion of the one study that enrolled only
ACEI-intolerant patients nor the exclusion of trials that
lasted less than six months changed the qualitative inter-
pretation of the pooled treatment effect on mortality or
Figure 2. Stratified comparisons of angiotensin receptor blockers (ARB) on all-cause mortality: ARB versus placebo, ARB versus angiotensin-converting
enzyme inhibitors (ACEI) and ARB-ACEI combination versus ACEI. Odds ratios (OR) and the 95% confidence intervals (CI) are shown on a logarithmic
scale, with box size proportional to the sample size. In each stratum, the diamond represents the pooled effect. Acronyms as in Abbreviations and Acronyms
box.
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hospitalization. A funnel plot for mortality showed no
obvious publication bias.
Study power. Post-hoc power calculations showed that our
meta-analysis had adequate power to detect at least a
moderate effect in favor of ARBs if ARBs were truly
efficacious over controls. At 90% power and a type I error
rate of 5%, our study was powered to detect an absolute risk
reduction of 2.0% or a relative risk reduction of 13.7% in
all-cause mortality in favor of ARBs when compared with
either placebo or ACEIs. For hospitalization for HF, our
Figure 3. Comparison of angiotensin receptor blockers versus controls on hospitalization for HF. Controls were either placebo or angiotensin-converting
enzyme inhibitors. Odds ratios (OR) and the 95% confidence intervals (CI) are shown on a logarithmic scale, with box size proportional to the sample size.
The diamond represents the pooled effect. Acronyms as in Abbreviations and Acronyms box.
Figure 4. Stratified comparisons of angiotensin receptor blockers (ARB) on hospitalization for HF: ARB versus placebo, ARB versus angiotensin-
converting enzyme inhibitor (ACEI) and ARB-ACEI combination versus ACEI. Odds ratios (OR) and the 95% confidence intervals (CI) are shown on
a logarithmic scale, with box size proportional to the sample size. In each stratum, the diamond represents the pooled effect. Acronyms as in Abbreviations
and Acronyms box.
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study was powered to detect an absolute risk reduction of
2.4% or a relative risk reduction of 13.9% from ARBs over
controls.
DISCUSSION
Evidence of benefit. Accumulated data to date cannot
confirm a clear-cut superiority of ARBs in reducing either
mortality or hospitalization when compared with controls.
Our primary analysis, however, may be considered conser-
vative given that 12 of the 17 trials had included ACEIs as
either controls or background therapy. The inclusion of
ACEIs, with a confirmed mortality and morbidity benefit,
thus tends to underestimate the true treatment benefit of
ARBs when compared with placebo controls alone. In fact,
when we considered only the trials in which ARBs were
compared with placebo without background ACEI therapy,
the direction of the observed benefits was in favor of ARBs.
Such a trend is reassurance to the use of ARBs as mono-
therapy in patients who are intolerant to ACEIs. In con-
trast, the virtually identical observed risks of both ARBs and
ACEIs in the stratified analysis is compatible with, though
not proof of, the hypothesis that ARBs and ACEIs may be
interchangeable when clinically warranted.
The absence of a clear benefit in favor of ARBs cannot be
solely attributed to a lack of power in our study. Pogue and
Yusuf (32) have argued that most interventions in contem-
porary cardiovascular medicine that are clinically important
reduce the relative risk of major outcomes by at least 15%.
Any observed reduction below this threshold may simply be
a result of statistical aberration and not truly represent a
biologically plausible or clinically reliable change. We have
shown that even if ARBs were truly efficacious, our meta-
analysis was unlikely to miss a relative risk reduction as large
as 13.9% in favor of ARBs. Our study is thus reliable in
excluding any favorable effect from ARBs—particularly over
ACEIs—that is of at least moderate size.
Heterogeneity of effect. The heterogeneity observed in the
pooled estimates in our primary analysis may be explained
by the trial designs—difference in the types of controls used,
inclusion of different ARBs and variation in the duration of
treatment. Analyses stratified by the types of controls indeed
reduced the observed heterogeneity. Similarly, readers
should be cautioned against the assumption that all ARBs
exert a similar “class” effect upon which this meta-analysis
is based. However, despite the known pharmacologic dif-
ferences between the various ARBs (33), there is currently
no definitive data to indicate that these differences have
impact on major clinical end points. Finally, our present
analysis cannot fully adjust for differences in the duration of
treatment between trials. Although it is possible that some
benefits of ARBs that were not detected in the early stages
would emerge over time, it should be noted that trials with
longer treatment periods did not show more favorable
pooled effects with ARBs than the remaining trials with
shorter treatment periods.
Sensitivity of effect. The observed pooled treatment effect
of ARBs on mortality was qualitatively robust. We viewed
the apparent sensitivity of the pooled treatment effect of
ARBs on hospitalization with particular caution. This is
because both the use of a fixed effects model and the use of
Peto OR (which inherently assumes a fixed effects model)
ignore the statistical and clinical heterogeneity we observed
in such a comparison. The Peto method also tends to yield
biased estimates when applied to unbalanced data such as
those in this meta-analysis (34).
Improvements over previous meta-analyses. Results of
our meta-analysis thus disagree with a previous meta-
analysis (4) that suggested an overall survival benefit with
losartan in HF. One source for this difference is the addition
of the results from the Evaluation of Losartan in the Elderly
(ELITE) II trial (5) to our analysis. ELITE II, published
subsequent to the previous meta-analysis, contradicted the
results of that meta-analysis and did not demonstrate a
survival benefit of losartan over captopril. The large weight
of that trial thus negated the favorable pooled effect dem-
onstrated in that meta-analysis. Furthermore, the aforemen-
tioned meta-analysis pooled exclusively trials that used only
losartan. In contrast, our analysis included trials with other
ARBs such as Randomized Evaluation of Strategies for Left
Ventricular Dysfunction pilot study (RESOLVD) (31)
(candesartan) and Val-HeFT (18) (valsartan), both of which
involved a significant cohort of patients.
Study limitations. Of all trials included in this meta-
analysis, only ELITE II and Val-HeFT were powered to
evaluate the mortality effect of ARBs as a primary outcome.
In addition, the limited sample sizes in other trials limited
the power of our stratified analyses to detect smaller, but
potentially clinically meaningful, benefits of ARBs when
compared with specific controls. On the other hand, the
lack of “mega-trials” dominating the stratified comparison
between ARBs and placebo reinforces the value of this
meta-analysis to succinctly summarize data from existing
smaller trials.
Inconsistent reports of other outcomes among the in-
cluded studies also prevented us from pooling other clini-
cally important end points. Although data from the ongoing
CHARM, OPTIMAAL and VALIANT trials may refine
our current conclusions in subsequent updates of this
meta-analysis, the results of all three trials are not expected
to be available until 2003, before which time this meta-
analysis will remain as the best overview of the current
evidence regarding the use of ARBs in the HF population.
Clinical implications. Our meta-analysis of 17 random-
ized controlled trials involving 12,649 patients with symp-
tomatic HF cannot confirm the superiority of ARBs in
reducing either all-cause mortality or hospitalization for
HF, particularly when compared with ACEIs. Current
evidence-based practice guidelines should continue to em-
phasize ACEIs as the primary pharmacologic therapy for
patients with HF. However, in patients whom ACEIs
cannot be given because of contraindications or intolerance,
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ARBs may be a reasonable substitute. Ongoing clinical trials
should help to resolve the definitive role of ARBs in the
treatment of HF—in particular as monotherapy in the
absence of ACEIs or as combination therapy with ACEIs.
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